Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed follicular non-Hodgkin's lymphoma~  * Diagnosed within the past 3 months~ * Grade 1, 2, or 3a disease~ * Stage II-IV disease~ * No evidence of histological transformation~* Bidimensionally measurable disease by clinical examination or radiography~* Asymptomatic disease without B symptoms or severe pruritus~* Low tumor burden, defined by all of the following criteria:~  * Lactic dehydrogenase normal~ * Largest nodal or extranodal mass \< 7 cm~ * No more than 3 nodal sites with a diameter \> 3 cm~ * No clinically detectable significant serous effusion by chest x-ray~    * Clinically non-evident small effusion on CT scan is not considered significant~ * Spleen enlargement ≤ 16 cm by CT scan~* Circulating tumor cells \< 5,000/mm\^3~* No organ compression (i.e., ureteric obstruction)~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Hemoglobin \> 10 g/dL~Hepatic~* AST and ALT normal~* Alkaline phosphatase normal~* Bilirubin normal~Renal~* Creatinine \< 2 times upper limit of normal (unless due to lymphoma)~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after completion of rituximab~* No known HIV positivity~* No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No critical organ failure~* No other immediate life-threatening disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior therapy for lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Watch and Wait (Type: ACTIVE_COMPARATOR): Watch and Wait - no treatment
- Arm C Rituximab 4 and Rixuximab Maintenance (Type: EXPERIMENTAL): 4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).